Kelly Wood, MD
Endocrinology, Diabetes & Metabolism · Fayetteville, GANPI 1710043492
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (55.1%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 26 manufacturers reported payments, led by Sanofi-aventis U.S. LLC at 47.6% of the total. Reporting peaked in 2019 at $3,949 and has fallen 75.9% since, to $951 in 2025.
Across 200 payments — averaging $41.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$4K
- Medtronic$1K
- Novo Nordisk$498
- AbbVie$394
- Abbott$334
- Amgen$296
- plus $2K from 20 others
What the payments were for
- Consulting fees$2,86034%
- Travel & lodging$86610%
- Food & beverage$4,60155%
- Education$300%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 29 | $3,978 |
| Medtronic(2 entities) | 15 | $1,216 |
| Novo Nordisk | 25 | $498 |
| AbbVie | 24 | $394 |
| Abbott | 18 | $334 |
| Amgen(2 entities) | 15 | $296 |
| Corcept Therapeutics | 8 | $243 |
| Radius Health, Inc. | 10 | $237 |
| Lilly USA, LLC | 9 | $175 |
| Insulet Corporation | 8 | $158 |
| Boehringer Ingelheim | 7 | $157 |
| Xeris Pharmaceuticals, Inc. | 5 | $110 |
| Tandem Diabetes Care, Inc. | 4 | $105 |
| Dexcom, Inc. | 4 | $85 |
| Kyowa Kirin, Inc. | 3 | $55 |
| IBSA Pharma Inc. | 3 | $54 |
| Bayer | 2 | $49 |
| Mannkind Corporation | 2 | $41 |
| Amneal Pharmaceuticals LLC | 2 | $37 |
| Globus Medical | 1 | $31 |
| Ascendis Pharma Endocrinology Inc | 1 | $25 |
| Amryt Pharma Holdings Ltd | 1 | $19 |
| AstraZeneca | 1 | $18 |
| Recordati_rare_diseases_inc. | 1 | $15 |
| Ascensia Diabetes Care US Inc. | 1 | $14 |
| Merck | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DISEASE STATE$2,860
- MINIMED 780G$849
- SOLIQUA 100/33$225
- TOUJEO$117
How this compares
$8,356 in reported general payments places this provider in the 75th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
See all endocrinology, diabetes & metabolism providers in Georgia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 388 | $673,572 |
| JardianceEmpagliflozin | 227 | $312,912 |
| MounjaroTirzepatide | 141 | $173,573 |
| FarxigaDapagliflozin Propanediol | 140 | $168,116 |
| TrulicityDulaglutide | 74 | $130,407 |
| JanuviaSitagliptin Phosphate | 92 | $104,238 |
| Tresiba Flextouch U-100Insulin Degludec | 106 | $75,147 |
| Tresiba Flextouch U-200Insulin Degludec | 57 | $68,547 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 36 | $45,075 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 54 | $42,061 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 26 | $33,409 |
| Novolog FlexpenInsulin Aspart | 99 | $27,279 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 22 | $27,164 |
| TradjentaLinagliptin | 26 | $26,747 |
| Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp | 78 | $25,627 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $498 | $677,527399 claims |
| Boehringer IngelheimJardiance, Tradjenta | $157 | $339,658253 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog Mix 75-25, Humulin 70-30 | $175 | $312,657246 claims |
| AstraZenecaFarxiga | $18 | $168,116140 claims |
| MerckJanuvia, Janumet, Janumet Xr | $13 | $137,014120 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $3,978 | $13,76511 claims |
| AbbVieSynthroid | $394 | $8,767108 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $37 | $4,792497 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
Other endocrinology, diabetes & metabolism in Fayetteville
- Bruce BodeAtlanta$1.5M
- David RobertsonAtlanta$1.4M
- Adeniyi OdugbesanLawrenceville$636K
- Miguel MunozMarietta$476K
- Jason BernerJasper$457K
- Dawn Smiley-ByrdTaylorsville$385K
- Barry JohnsMacon$335K
- Jonathan OwnbyAtlanta$291K
- Ismary DecastroSavannah$169K
- Naland ShenoySnellville$139K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.